A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy.

Nephrol Dial Transplant 2018 09;33(9):1628-1635

Department of Renal Medicine, Eastern Health, Melbourne, VIC, Australia.

Background: Intravenous (IV) iron can modulate fibroblast growth factor 23 (FGF23) concentrations and cause transient but significant hypophosphataemia. However, it is unknown what other markers might be involved, especially in different patient groups. This study aimed to determine changes in bone and haematinic biomarkers following IV ferric carboxymaltose (FCM) and to identify risk factors for hypophosphataemia in pregnant subjects and those with chronic kidney disease (CKD).

Methods: Changes in bone [serum FGF23, fractional excretion of phosphate urinary fractional excretion of phosphate (FEPi), serum phosphate and serum vitamin D derivatives] and haematinic [plasma hepcidin, serum ferritin and transferrin saturation (TSAT)] biomarkers after 1 g of IV FCM were followed in iron-deficient pregnant and CKD patients and compared with controls (estimated glomerular filtration rate > 60 mL/min/1.73 m2). Data were collected at baseline and up to 42 days after infusion. Risk factors for post-FCM hypophosphataemia were also assessed.

Results: Sixty-five subjects completed the study (control, n = 20; pregnant, n = 20; CKD, n = 25). A uniform but variable increase across groups was seen in intact FGF23 (peak Day 2), whereas c-terminal FGF23 varied markedly. Trough serum phosphate timed with the peak FEPi at Day 7, recovering by Day 21 in the pregnant group and Day 42 in other groups. Independent predictors of a low phosphate nadir included baseline phosphate, FEPi and weight-adjusted FCM dose. All groups showed an early and marked increase in plasma hepcidin (peak Day 2), serum ferritin and TSAT (peak Day 7 for both).

Conclusions: Changes in bone and haematinic biomarkers differ between patient groups following IV FCM. For patients with lower serum phosphate concentrations, limiting the dose and measuring levels 7 days after administration may mitigate clinically significant hypophosphataemia.

Download full-text PDF

Source
http://dx.doi.org/10.1093/ndt/gfx310DOI Listing
September 2018
37 Reads

Publication Analysis

Top Keywords

serum phosphate
12
bone haematinic
12
peak day
12
changes bone
12
haematinic biomarkers
12
kidney disease
8
risk factors
8
excretion phosphate
8
fractional excretion
8
phosphate fepi
8
chronic kidney
8
ferric carboxymaltose
8
patient groups
8
serum ferritin
8
phosphate
7
serum
6
day
6
groups
5
pregnant n = 20
4
n = 20 pregnant
4

References

(Supplied by CrossRef)
Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal FGF23 levels of maintenance hemodialysis patients
Nephrology (Carlton) 2016

Similar Publications